Literature DB >> 15648244

Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not.

Manmohan Singh1, James Chesko, Jina Kazzaz, Mildred Ugozzoli, Elaine Kan, Indresh Srivastava, Derek T O'Hagan.   

Abstract

PURPOSE: To evaluate the delivery of a novel HIV-1 antigen (gp120dV2 SF162) by surface adsorption or encapsulation within polylactide-co-glycolide microparticles and to compare both the formulations for their ability to preserve functional activity as measured by binding to soluble CD4.
METHODS: Poly(lactide-co-glycolide) microparticles were synthesized by a water-in-oil-in-water (w/o/w) emulsification method in the presence of the anionic surfactant dioctylsulfosuccinate (DSS) or polyvinyl alcohol. The HIV envelope glyocoprotein was adsorbed and encapsulated in the PLG particles. Binding efficiency and burst release measured to determine adsorption characteristics. The ability to bind CD4 was assayed to measure the functional integrity of gp120dV2 following different formulation processes.
RESULTS: Protein (antigen) binding to PLG microparticles was influenced by both electrostatic interaction and other mechanisms such as hydrophobic attraction and structural accommodation of the polymer and biomolecule. The functional activity as measured by the ability of gp120dV2 to bind CD4 was maintained by adsorption onto anionic microparticles but drastically reduced by encapsulation.
CONCLUSIONS: The antigen on the adsorbed PLG formulation maintained its binding ability to soluble CD4 in comparison to encapsulation, demonstrating the feasibility of using these novel anionic microparticles as a potential vaccine delivery system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15648244     DOI: 10.1007/s11095-004-7666-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

Review 1.  HIV vaccines.

Authors:  S E Frey
Journal:  Infect Dis Clin North Am       Date:  1999-03       Impact factor: 5.982

2.  Predicting the adsorption of proteins by aluminium-containing adjuvants.

Authors:  S J Seeber; J L White; S L Hem
Journal:  Vaccine       Date:  1991-03       Impact factor: 3.641

3.  The importance of surface charge in the optimization of antigen-adjuvant interactions.

Authors:  P M Callahan; A L Shorter; S L Hem
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

4.  Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

Authors:  J Kazzaz; J Neidleman; M Singh; G Ott; D T O'Hagan
Journal:  J Control Release       Date:  2000-07-03       Impact factor: 9.776

5.  Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.

Authors:  D O'Hagan; M Singh; M Ugozzoli; C Wild; S Barnett; M Chen; M Schaefer; B Doe; G R Otten; J B Ulmer
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

Review 6.  New therapies on the horizon for hepatitis C.

Authors:  Silvia C Sookoian
Journal:  Ann Hepatol       Date:  2003 Oct-Dec       Impact factor: 2.400

7.  Recombinant human erythropoietin (rhEPO) loaded poly(lactide-co-glycolide) microspheres: influence of the encapsulation technique and polymer purity on microsphere characteristics.

Authors:  B Bittner; M Morlock; H Koll; G Winter; T Kissel
Journal:  Eur J Pharm Biopharm       Date:  1998-05       Impact factor: 5.571

8.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.

Authors:  P D Kwong; R Wyatt; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

9.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

Review 10.  Prospects for an AIDS vaccine: three big questions, no easy answers.

Authors:  David A Garber; Guido Silvestri; Mark B Feinberg
Journal:  Lancet Infect Dis       Date:  2004-07       Impact factor: 25.071

View more
  6 in total

1.  Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens.

Authors:  Jigna D Patel; Ronan O'Carra; Julia Jones; Jerold G Woodward; Russell J Mumper
Journal:  Pharm Res       Date:  2006-12-19       Impact factor: 4.200

2.  Antibody response to polyhistidine-tagged peptide and protein antigens attached to liposomes via lipid-linked nitrilotriacetic acid in mice.

Authors:  Douglas S Watson; Virginia M Platt; Limin Cao; Vincent J Venditto; Francis C Szoka
Journal:  Clin Vaccine Immunol       Date:  2010-12-15

3.  Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen.

Authors:  Mauricio A Arias; Andrew Loxley; Christy Eatmon; Griet Van Roey; David Fairhurst; Mark Mitchnick; Philip Dash; Tom Cole; Frank Wegmann; Quentin Sattentau; Robin Shattock
Journal:  Vaccine       Date:  2010-12-09       Impact factor: 3.641

4.  Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines.

Authors:  Fausto Titti; Maria T Maggiorella; Flavia Ferrantelli; Leonardo Sernicola; Stefania Bellino; Barbara Collacchi; Emanuele Fanales Belasio; Sonia Moretti; Maria Rosaria Pavone Cossut; Roberto Belli; Erika Olivieri; Stefania Farcomeni; Daniela Compagnoni; Zuleika Michelini; Michela Sabbatucci; Katia Sparnacci; Luisa Tondelli; Michele Laus; Aurelio Cafaro; Antonella Caputo; Barbara Ensoli
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

Review 5.  Technological approaches to streamline vaccination schedules, progressing towards single-dose vaccines.

Authors:  Giuseppe Lofano; Corey P Mallett; Sylvie Bertholet; Derek T O'Hagan
Journal:  NPJ Vaccines       Date:  2020-09-18       Impact factor: 7.344

6.  Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.

Authors:  Christopher J Genito; Cole J Batty; Eric M Bachelder; Kristy M Ainslie
Journal:  Adv Nanobiomed Res       Date:  2021-01-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.